DCAT Week ’17 Member Company Announcement Forum: Tracking the Pharma Manufacturing Value Chain
By

Senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions, at the DCAT Member Company Announcement Forum at DCAT Week ’17. DCAT Value Chain Insights highlights the latest developments.

Developments in Drug-Substance Manufacturing
Noramco CEO Discusses Strategy as Stand-Alone Company

Patheon Integrates Former Roche API Manufacturing Facility

BioVectra Outlines API Manufacturing Expansion

Novasep Opens New Bioconjugation Facility for ADCs

Olon Highlights Integration of Infa

CMC Biologics Updates Acquisition by AGC Asahi Glass

Developments in Drug-Product Development and Manufacturing
Mayne Pharma Specifies Timeline for $80-Million Expansion

Catalent Integrates Pharmatek and Accucaps Acquisitions

Lubrizol’s Particle Sciences Expands Manufacturing

Developments in both Drug Substance and Drug Product Manufacturing:
Siegfried CEO Outlines Five-Year Strategic Plan

CordenPharma Expands Oligonucletides and Sterile Injectables

Developments in Packaging
Datwyler Outlines $100-Million Manufacturing Expansion

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The Year Ahead: What’s on the Minds of CEOs?
By

By
Economic uncertainty, supply chain, talent management, and risk mitigation were key issues cited by CEOs in PwC’s Global CEO survey, released at the World Economic Forum in Davos, Switzerland. What are key takeaways from a study of 4,400 CEOs?

Big Pharma’s Growth Initiatives in 2023: Part 2
By

By
More coverage of the J.P. Morgan Annual Healthcare Conference in San Francisco earlier this month, where bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives. What are more highlights?

The CDMO/CMO Report: The Year Ahead in Bio/Pharma Outsourcing
By

By
What can the markets for bio/pharmaceutical outsourcing expect in 2023? DCAT Value Chain Insights examines key trends and highlights in major manufacturing segments: API and drug-product manufacturing. 

Big Pharma Strategies and Growth Initiatives: What’s In Store for 2023
By

By
At the J.P. Morgan Annual Healthcare Conference in San Francisco this week, bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives.